Ignite Creation Date:
2025-12-25 @ 4:16 AM
Ignite Modification Date:
2025-12-26 @ 3:16 AM
Study NCT ID:
NCT06040320
Status:
RECRUITING
Last Update Posted:
2025-10-28
First Post:
2023-09-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Sponsor:
Washington University School of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-04
Start Date Type:
ACTUAL
Primary Completion Date:
2027-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-09
First Submit QC Date:
None
Study First Post Date:
2023-09-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-25
Last Update Post Date:
2025-10-28
Last Update Post Date Type:
ESTIMATED